Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — Shareholder Meeting (November 2025)
31 slides from Bcal Diagnostics's shareholder meeting presentation, November 2025
Slide 1: Chair's Address to the 2025 AGM
BCAL Diagnostics – Chair’s Address to the 2025 AGM Good morning shareholders, colleagues, partners and guests. Thank you for joining us at the 2025 Annual General Meeting of BCAL Diagnostics. It is my privilege to present this year’s Chair’s Address, and to reflect on our progress, our challenges, ou
Slide 2: Chair's address: convertible note and priorities
We remain transparent about our position: revenue growth is still in its early stages. Adoption curves in diagnostics take time, and our strategy is designed around this reality. Today, shareholders will consider a $10 million convertible note facility, with $5 million already firmly committed. This
Slide 3: Chair's address: early detection and biobank
to modern diagnostics improves outcomes and can reduce long-term health expenditure. To secure government support, compelling health economics are essential. We continue to work with policymakers, regulators and clinical leaders to demonstrate measurable value to the health system. This aligns with
Slide 4: Chair's address: thanks and FY26 outlook
I would like to thank the BCAL Board for their exceptional commitment and guidance. I also acknowledge former Directors Ronald Phillips and Mark Burrows, who stepped down in 2025. Their leadership helped shape BCAL into the organisation it is today. To our shareholders, thank you for your trust and
Slide 5: Annual General Meeting November 2025
November 2025 Annual General Meeting Executive Chair Jayne Shaw Chief Executive Officer Shane Ryan Chief Commercial Officer Chris Baldwin
Slide 6: Board and Management
Board and Jayne Shaw Executive Chair Jonathan Trollip Non-Executive Director David Darling Non-Executive Director Management Dr John Hurrell Shane Ryan Chris Baldwin Non-Executive Director Chief Executive Officer Chief Commercial Officer BCAL Diagnostics FY25 AGM Presentation 2
Slide 7: Chair's Address
Chair’s Address
Slide 8: FY25 highlights
FY25 highlights Commercial launch of BREASTEST plus in Sydney Australia (March 2025) Early detection portfolio expanded through ClearNote Health Partnership (Sept 2025) 209 BREASTEST plus Consumer campaign reaching Strategic partnerships with tests sold in the first two >500,000 women, multiple Sydn
Slide 9: Formal Business
Formal Business
Slide 10: Resolution - Remuneration Report
Formal business RESOLUTION 1 - REMUNERATION REPORT To consider, and if thought fit, to pass the following resolution as a non-binding ordinary resolution: “That for the purposes of section 250R of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration
Slide 11: Resolution - Re-election of Director: Jonathan Trollip
Formal business RESOLUTION 2 - RE-ELECTION OF DIRECTOR: MR JONATHAN TROLLIP To consider, and if thought fit, to pass the following as an ordinary resolution: “That Mr Jonathan Trollip, who retires by rotation in accordance with Rule 8.6 of the Company’s constitution and Listing Rule 14.4 and, being
Slide 12: Resolution - Approval of Convertible Note Facility
Formal business RESOLUTION 3 – APPROVAL OF CONVERTIBLE NOTE FACILITY AND SHARES TO BE ISSUED UNDER THE FACILITY To consider, and if thought fit, to pass the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the Conve
Slide 13: Resolution - Additional 10% Placement Capacity
Formal business RESOLUTION 4 – APPROVAL OF ADDITIONAL 10% PLACEMENT CAPACITY To consider and, if thought fit, to pass the following resolution as a special resolution: "That, for the purposes of ASX Listing Rule 7.1A and all other purposes, approval is given for the Company to allot and issue Equity
Slide 14: CEO Address
CEO Address
Slide 15: Looking back at 2024 AGM: BCAL Diagnostics delivered
Looking back at 2024 AGM: BCAL Diagnostics delivered 2025 Objectives Market Access Strategy KOL Network Industry Partnerships Talent and Team US Program By building the science, the team and the relationships needed to launch and support BREASTEST plus, BCAL demonstrated to the industry that it is a
Slide 16: 2025: Building the engine for success
2025: Building the engine for success Market Access Strategy & Sales Volume Expanding channels & driving volume to market through GPs & Specialist nationally Product Global Development Continue to build sales team, awareness & leverage AI and digital platforms Partnering Solving clinical gaps in Est
Slide 17: Capabilities attract strong strategic partners
Capabilities attract strong strategic partners BCAL Diagnostics FY25 AGM Presentation 7
Slide 18: BCAL can leverage its commercial and lab investments to expand offerings
BCAL can leverage its commercial and lab investments to expand offerings BREASTEST Next Gen Avantect Ovarian Avantect test MCD test Avantect BREASTEST Pancreatic plus Test BCAL Diagnostics FY25 AGM Presentation 14
Slide 19: AI supported digital channels are educating patients and reaching HCPs
AI supported digital channels are educating patients and reaching HCPs https://densebreasts.com.au Website providing information for women about breast density, breast cancer screening and risk management Aligned with digital GP & consumer campaigns and educational webinar Women can reach out to BCA
Slide 20: Looking forward to 2026 AGM: BCAL Diagnostics will deliver
Looking forward to 2026 AGM: BCAL Diagnostics will deliver Q1 Q2 Q3 Q4 Expand BREASTEST plus footprint across Melbourne and Brisbane; initiate regional rollout program Sydney market launch of Avantect® Ovarian and Pancreatic tests BREASTEST plus incorporated into Best Practice GP management software
Slide 21: ClearNote Health
ClearNote Health
Slide 22: Who is ClearNote Health?
Who is ClearNote Health? History Technology leader Global validation • ClearNote Health is a US based • Virtuoso epigenomics platform • CLIA/CAP-accredited lab in San company transforming cancer powered by AI & bioinformatics Diego, UKCA-marked in the UK. detection through early, accurate, used by N
Slide 23: BCAL and ClearNote Health partnership
BCAL and ClearNote Health partnership ClearNote Health - a US based company - has selected BCAL to deliver their cutting-edge early detection cancer tests in Australia and New Zealand BCAL has exclusive rights to distribute ClearNote’s Avantect Pancreatic and Avantect Ovarian tests for an initial tw
Slide 24: The importance of early detection on survival
The importance of early detection on survival Today, survival rates are extremely Pancreatic 3% VS >80% unlikely as most pancreatic cancer is Cancer diagnosed at Stage IV By detecting Cancer at Stage IA, early 5-year relative survival for 5-year survival at stage IA1 detection makes pancreatic cance
Slide 25: Avantect early-stage detection tests are accurate and in clinical use globally
Avantect early-stage detection tests are accurate and in clinical use globally In use commercially in US, with reimbursement from major insurers Pancreatic 68.3% 96.9% UK regulatory approvals Test Australian regulatory pathway clear Major clinical trials underway: 1. SAFE-D (UK) Sensitivity Specific
Slide 26: Avantect tests have clinical utility in significant populations
Avantect test have clinical utility in significant populations Pancreatic Ovarian • New onset diabetes • Personal histories of breast cancer • Individuals with familial pancreatic cancer histories • Individuals with familial breast or ovarian cancer • Genetic predispositions (e.g. BRCA1/2) histories
Slide 27: Avantect tests are more reliable than national screens for other cancers
Avantect tests are more reliable than national screens for other cancers 1. Sensitivity: How often is the cancer detected? (The higher, the more lives saved) 2. Specificity: How often do healthy patients receive a “not-detected” result? (The higher, the fewer unnecessary referrals.) 100% The “perfec
Slide 28: Future tests: Avantect multi-cancer update
Future tests: Avantect multi-cancer update Major clinical trial underway Accuracy across seven cancer types VANGUARD (US) • Healthy adults (45-75 yrs) • 24,000 patients across three arms Objectives 56.3% 98.4% • Timeliness and logistics of returning MCD test results. • Diagnostic resolution of abnor
Slide 29: Introducing earlydetection.com.au
Introducing earlydetection.com.au Information portal providing information about early cancer detection to patients. Today: Sign up for more information Jan 2026: Access to telehealth appointments with medical professionals BCAL Diagnostics FY25 AGM Presentation 25
Slide 30: Thank you and closing remarks from Executive Chair Jayne Shaw
20XX Thank you and closing remarks from Executive Chair Jayne Shaw Jayne Shaw Shane Ryan Chris Baldwin Executive Chair Chief Executive Officer Chief Commercial Officer jshaw@bcaldiagnostics.com sryan@bcaldiagnostics.com cbaldwin@bcaldiagnostics.com 26
Slide 31: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by BCAL Diagnostics The forward-looking statements are based on information available to BCAL Not An Offer Ltd ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change and the This Presentati
BCAL Diagnostics — Shareholder Meeting (November 2025) on 6ix